Intravenous contrast material application in high-risk patients is unlikely to be associated with permanent adverse outcomes. SCr levels after contrast material administration are lower in iodixanol than iopromide groups.

Split-bolus injection provides sufficient attenuation for visualization of the right heart, while streak artifacts from high-attenuation contrast material can generally be avoided and arterial attenuation is maintained.

No abstract

Myocardial T1-mapping has become feasible over the past decade as emerging technological magnetic resonance imaging advances enable increasingly rapid and reliable acquisition techniques. A variety of T1-mapping sequences are in development, with most allowing for the acquisition of a single-slice T1-map in a single breath-hold. The development of these protocols has spurred investigation into a wide range of potential clinical uses, including the characterization of cardiomyopathies. Although native T1-mapping provides superior tissue characterization, postcontrast T1-mapping is still indispensable for extracellular volume quantification. Ongoing and future studies should investigate the reliability, reproducibility, accuracy, and precision of available techniques and establish disease-specific reference values for T1-mapping-based parameters.

Noncontrast QISS-MRA provides high diagnostic accuracy compared with DSA, while being less prone to image artifacts than CTA. QISS better visualizes heavily calcified segments with impaired flow. QISS-MRA obviates the need for contrast administration in PAD patients.